Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Isis Innovation and Parkwalk Advisors announced today that the University of Oxford Isis Fund II has raised over £2 million, exceeding its funding target, and will close to new investors.

The fund achieved its initial target in less than four weeks and will close at almost twice that level.

Isis Innovation executive director Linda Naylor said: “In 2014, Isis Innovation oversaw a record £2.6m in proof-of-concept funding flow into over twenty new Oxford technologies and ventures. The first University of Oxford Isis Fund was a cornerstone of this achievement, and we already have a pipeline of promising technologies which will apply to this second Fund over the coming year.

“These Funds will again play a critical role in providing finance so new companies are properly resourced for the initial stages of commercial product development.”

The University of Oxford Isis Fund I invested in stroke-diagnostics specialist Brainomix which went on to raise £1.2m and won numerous awards and grants, Oxtex, the developer of a novel intelligent tissue expander, Salunda, the manufacturer of a contactless sensor for condition monitoring and automated sentiment analysis company TheySay.

Parkwalk Advisors’ Moray Wright said: “These Funds provides private investors, particularly University of Oxford alumni and friends, with quite a unique chance to invest in early stage technology companies as they spin-out of the University.

“And as these companies become successful, investors in the funds also stand to gain from the tax reliefs offered under the Enterprise Investment Scheme and Seed Enterprise Investment Scheme.”

Since 1987, Isis Innovation has been responsible for creating spin-out companies based on academic research from the University of Oxford. It has spun-out a new company every two months on average. Over £266 million in external investment has been raised by Isis spin-out companies since 2000, and five are currently listed on London’s AIM market.

Parkwalk Advisors is a UK technology-specialist EIS fund management firm. Parkwalk aims to launch the University of Oxford Isis Fund III in Q4 2015 or Q1 2016. For further details please contact the Parkwalk funds team on 020 7759 2285.

About Isis Innovation

Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.

Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 503 licenses and consulting agreements. Isis Enterprise, our innovation management consultancy, signed 85 deals with university, government and industrial clients from offices around the world.

Isis was named ‘Technology Transfer Unit of the Year 2014’ by Global University Venturing.

For updates on innovations from Oxford, follow Isis on LinkedIn and Twitter or subscribe at www.isis-innovation.com 

About Parkwalk Advisors

Specialising in University spin-out companies, Parkwalk invests in innovative UK high-growth companies across various stages of their development: from growth, development and commercial capital through to acquisition finance. Investments range from early stage to AIM-listed. Parkwalk’s EIS Funds seek significant capital gains with the substantial benefits offered under the Enterprise Investment Scheme. 

For updates from Parkwalk, please go to www.parkwalkadvisors.com or follow us on Twitter

For further details please contact the Parkwalk funds team on 020 7759 2285.

Media enquiries to:

Renate Krelle
Media & Business Communications Manager, Isis Innovation Ltd
renate.krelle@isis.ox.ac.uk
T: 01865 280867

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.